Nanjing Vishee Medical Technology (688580) Fundamentals 2026 — P/E 27.7x, Revenue Analysis | SniperIQ
Nanjing Vishee Medical Technology (688580) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of ¥4.6B, trading at ¥47.69 on the SHH. This SniperIQ fundamentals page covers Nanjing Vishee Medical Technology's valuation (P/E 27.7x, P/B 2.6x), profitability (net margin 34.9%), revenue (¥463M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Nanjing Vishee Medical Technology's market cap?
Nanjing Vishee Medical Technology (688580) has a market capitalization of approximately ¥4.6B, trading at ¥47.69 on the SHH. Market cap moves with the live share price.
What is Nanjing Vishee Medical Technology's P/E ratio?
Nanjing Vishee Medical Technology's trailing twelve-month P/E ratio is 27.7x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Nanjing Vishee Medical Technology?
Nanjing Vishee Medical Technology runs a net profit margin of 34.9%, a gross margin of 99.2%, and an operating margin of 30.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Nanjing Vishee Medical Technology generate?
Nanjing Vishee Medical Technology reported revenue of ¥463M for fiscal year 2025, with net income of ¥138M and earnings per share (EPS) of 1.44. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Nanjing Vishee Medical Technology pay a dividend?
Nanjing Vishee Medical Technology offers a trailing dividend yield of about 2.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Nanjing Vishee Medical Technology financially healthy?
Nanjing Vishee Medical Technology carries a debt-to-equity ratio of 0.00x and a current ratio of 9.65x, with a market beta of 0.56. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Nanjing Vishee Medical Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nanjing Vishee Medical Technology (688580) the key facts are: market cap ¥4.6B, P/E 27.7x, revenue ¥463M, 52-week range 43.2-72.27. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Nanjing Vishee Medical Technology's full fundamentals live
Get Nanjing Vishee Medical Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.